Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog – Page 4208

Summary: Researchers have identified a protein that could be leveraged to help microglia in the brain stave off Alzheimer’s and other neurodegenerative diseases.

Source: The Conversation.

Many neurodegenerative diseases, or conditions that result from the loss of function or death of brain cells, remain largely untreatable. Most available treatments target just one of the multiple processes that can lead to neurodegeneration, which may not be effective in completely addressing disease symptoms or progress, if at all.

Read more | >

The drug, midazolam, is often used before surgery to make a patient feel more relaxed. According to a new study, it is associated with an increased risk of heart damage when surgeries are performed at night.

According to a study conducted by researchers at the University of Colorado Anschutz Medical Campus, a popular drug that makes patients sleepy and less anxious before surgery is associated with an increased risk of heart damage when surgeries are performed at night.

The results provide further proof that a drug’s effectiveness might vary depending on the time it is administered.

Read more | >

Furstenberg’s Proof

Szemerédi had been examining sets that contain a “positive fraction” of all the integers. Take, for example, the set containing all multiples of 5. As you look at bigger and bigger swaths of the number line, multiples of 5 continue to appear regularly. Mathematicians say that the set containing all multiples of 5 has the fraction of a fifth of all the integers.

Read more | >

Robots and AI are already real products and services. But will they take our jobs? Or even take over? In this video I discuss these questions in a pragmatic fashion, as well as how we may usefully define “artificial intelligence”. Also covered are cloud AI services, and the role AI in digital transformation.

REFERENCES & OTHER LINKS:

Alan Turing’s 1950 paper in “Mind” on ‘Computing Machinery and Intelligence’:
https://www.csee.umbc.edu/courses/471/papers/turing.pdf.

IBM Watson (cloud AI):

Continue reading “AI, Robots & the Future” | >

The Tokyo-based company will also achieve the first Japanese lunar landing.

Tokyo-based ispace is set to become the world’s first private company to land a lunar lander on the moon this December. “ispace, inc., a global lunar exploration company, released an updated launch schedule for its Mission 1 (M1) lunar lander, now scheduled to liftoff from SLC-40 from Cape Canaveral Space Force Station no earlier than Dec. 11, 2022. The M1 lander, part of the HAKUTO-R lunar exploration program, will launch on a SpaceX Falcon 9 rocket,” said a press statement on ispace’s website.

The mission was initially scheduled to launch on November 30, but the launch date was delayed.

ispace.

Continue reading “Japan’s ispace set to become the first private firm to launch a lunar lander on the moon” | >

It is working with CERN to push the boundaries of clean aerospace.

Airbus and CERN, the European Laboratory for Particle Physics, have joined forces to launch Airbus UpNext, a project whose aim is to evaluate how superconductivity can contribute to the decarbonization of future aircraft systems, according to a press release by the aircraft manufacturer published last week.

It consists of a Super-Conductor for Aviation with Low Emissions (SCALE) demonstrator that aims to promote the adaptation and adoption of superconducting technologies in airborne electrical distribution systems.

Read more | >

What alternative sex-determining system will we adapt?

The sex of human and other mammal babies is decided by a male-determining gene on the Y chromosome. But the human Y chromosome is degenerating and may disappear in a few million years, leading to our extinction unless we evolve a new sex gene.

A new paper in Proceedings of the National Academy of Science shows how the spiny rat has evolved a new male-determining gene.

Usis/iStock.

Continue reading “Men are losing their Y chromosome, and rats could show our future” | >

It has been described as “bringing your army right to the enemy.”

There’s a promising new therapy that makes the immune system kill bone marrow cancer cells. It has thus far been successful in as many as 73 percent of patients in two clinical trials, according to a report released by researchers from The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai.

The novel therapy, called talquetamab, binds to both T cells and multiple myeloma cells and directs the T cells to exterminate multiple myeloma cells. It has been described as “bringing your army right to the enemy.”

Talquetamab was tested in phase 1 and phase 2 trials.

Continue reading “‘New lease on life’: Bone marrow cancer therapy successful in 73% of patients” | >